Wolfgang Fendler is a Senior Consultant and Vice Chair at the Clinic for Nuclear Medicine, Essen University Hospital, Essen, Germany. He also heads the research group “Translational Oncology” at the institution. Since January 2021, he is an apl. Professor at the medical faculty, University of Duisburg-Essen. He obtained his M.D. from the Ludwig-Maximilians-Universität (LMU) Munich with the thesis titled, “CD103 and LPAM: role in recruitment of regulatory T cells into malignant tumours.” Dr Fendler has authored 123 peer-reviewed articles in several journals such as Clinical Cancer Research, Lancet Oncology, JAMA Oncology, and Journal of Nuclear Medicine. He is on the editorial board of Journal of Nuclear Medicine and has been a reviewer for European Urology, European Clinical Cancer Research, BMC Cancer, PLOS ONE among other journals. He was the co-investigator, clinical study report author and was involved in the clinical trial design and data analysis of the study leading to the FDA Approval for 68Ga-PSMA-11 PET. He is currently serving as an investigator in trials in prostate cancer and thyroid cancer. He is a member of the German Society for Nuclear Medicine, European Association of Nuclear Medicine, and European Association of Urology.
EM-75184 - Date of preparation: September 2021